This model is a powerful tool that allows us to characterize the interplay between FLT3-ITD and DNMT3A mutations in the development and maintenance of both myeloid and lymphoid leukemias, and provides a novel clinically-relevant model for the development and evaluation of therapies for acute leukemia. Here, DNMT3A is linked to lymphoid leukemia.